{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:51:23Z","timestamp":1745470283847},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00108-022-01463-0","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T12:03:03Z","timestamp":1673870583000},"page":"113-120","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Parkinson-Krankheit und Demenz vom Alzheimer-Typ\u00a0\u2013 Pathophysiologie und medikament\u00f6se Therapieans\u00e4tze","Parkinson\u02bcs disease and Alzheimer type dementia\u2014Pathophysiology and drug treatment approaches"],"prefix":"10.1007","volume":"64","author":[{"given":"Richard","family":"Dodel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"issue":"1","key":"1463_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne\u00a0VL, Fodero-Tavoletti\u00a0MT, Masters\u00a0CL, Rowe\u00a0CC (2015) Tau imaging: early progress and future directions. Lancet Neurol 14(1):114\u2013124","journal-title":"Lancet Neurol"},{"issue":"4","key":"1463_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14737159.2022.2068952","volume":"22","author":"MF Beatino","year":"2022","unstructured":"Beatino\u00a0MF, De Luca\u00a0C, Campese\u00a0N, Belli\u00a0E, Piccarducci\u00a0R, Giampietri\u00a0L et al (2022) \u03b1\u2011synuclein as an emerging pathophysiological biomarker of Alzheimer\u2019s disease. Expert Rev Mol Diagn 22(4):411\u2013425","journal-title":"Expert Rev Mol Diagn"},{"issue":"s1","key":"1463_CR3","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.3233\/JPD-179001","volume":"7","author":"H Braak","year":"2017","unstructured":"Braak\u00a0H, Del Tredici\u00a0K (2017) Neuropathological staging of brain pathology in sporadic Parkinson\u2019s disease: separating the wheat from the chaff. J\u00a0Parkinsons Dis 7(s1):S71\u2013S85","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"1463_CR4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0896-6273(95)90302-X","volume":"14","author":"A Iwai","year":"1995","unstructured":"Iwai\u00a0A, Masliah\u00a0E, Yoshimoto\u00a0M, Ge\u00a0N, Flanagan\u00a0L, de Silva\u00a0HA et al (1995) The precursor protein of non\u2011A beta component of Alzheimer\u2019s disease amyloid is a\u00a0presynaptic protein of the central nervous system. Neuron 14(2):467\u2013475","journal-title":"Neuron"},{"key":"1463_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/bs.pbr.2019.10.005","volume":"252","author":"IC Bras","year":"2020","unstructured":"Bras\u00a0IC, Xylaki\u00a0M, Outeiro\u00a0TF (2020) Mechanisms of alpha-synuclein toxicity: An update and outlook. Prog Brain Res 252:91\u2013129","journal-title":"Prog Brain Res"},{"key":"1463_CR6","doi-asserted-by":"publisher","first-page":"114059","DOI":"10.1016\/j.bbr.2022.114059","volume":"436","author":"WP Ruf","year":"2023","unstructured":"Ruf\u00a0WP, Meirelles\u00a0JL, Danzer\u00a0KM (2023) Spreading of alpha-synuclein between different cell types. Behav Brain Res 436:114059","journal-title":"Behav Brain Res"},{"issue":"1","key":"1463_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/nan.12298","volume":"42","author":"K Del Tredici","year":"2016","unstructured":"Del Tredici\u00a0K, Braak\u00a0H (2016) Review: Sporadic Parkinson\u2019s disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol 42(1):33\u201350","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"1463_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp.72.1.12","volume":"72","author":"HA Ring","year":"2002","unstructured":"Ring\u00a0HA, Serra-Mestres\u00a0J (2002) Neuropsychiatry of the basal ganglia. J\u00a0Neurol Neurosurg Psychiatry 72(1):12\u201321","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1463_CR9","doi-asserted-by":"publisher","DOI":"10.1055\/b-006-163222","volume-title":"Parkinson-Syndrome und andere Bewegungsst\u00f6rungen","author":"G Deuschl","year":"2020","unstructured":"Deuschl\u00a0G, Oertel\u00a0WH, Poewe\u00a0W (2020) Parkinson-Syndrome und andere Bewegungsst\u00f6rungen. Thieme, Stuttgart"},{"key":"1463_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neuroscience.2011.06.048","volume":"198","author":"T Wichmann","year":"2011","unstructured":"Wichmann\u00a0T, Dostrovsky\u00a0JO (2011) Pathological basal ganglia activity in movement disorders. Neuroscience 198:232\u2013244","journal-title":"Neuroscience"},{"issue":"6","key":"1463_CR11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1055\/s-0034-1366372","volume":"82","author":"EA Pelzer","year":"2014","unstructured":"Pelzer\u00a0EA, Hintzen\u00a0A, Timmermann\u00a0L, Tittgemeyer\u00a0M (2014) Satellite systems of the basal ganglia\u2014Anatomic position, clinical relevance. Fortschr Neurol Psychiatr 82(6):323\u2013329","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"4","key":"1463_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3233\/JPD-229002","volume":"12","author":"K McFarthing","year":"2022","unstructured":"McFarthing\u00a0K, Rafaloff\u00a0G, Baptista\u00a0M, Mursaleen\u00a0L, Fuest\u00a0R, Wyse\u00a0RK et\u00a0al (2022) Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2022 update. J\u00a0Parkinsons Dis 12(4):1073\u20131082","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"1463_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","volume":"29","author":"PV Fish","year":"2019","unstructured":"Fish\u00a0PV, Steadman\u00a0D, Bayle\u00a0ED, Whiting\u00a0P (2019) New approaches for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 29(2):125\u2013133","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"1463_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1358\/dot.2022.58.10.3422314","volume":"58","author":"M Tagliapietra","year":"2022","unstructured":"Tagliapietra\u00a0M (2022) Aducanumab for the treatment of Alzheimer\u2019s disease. Drugs Today (Barc) 58(10):465\u2013477","journal-title":"Drugs Today (Barc)"},{"issue":"10","key":"1463_CR15","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","volume":"79","author":"S Shcherbinin","year":"2022","unstructured":"Shcherbinin\u00a0S, Evans\u00a0CD, Lu\u00a0M, Andersen\u00a0SW, Pontecorvo\u00a0MJ, Willis\u00a0BA et al (2022) Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol 79(10):1015\u20131024","journal-title":"JAMA Neurol"},{"issue":"1","key":"1463_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P, Bateman\u00a0RJ, Chen\u00a0C, Gee\u00a0M et\u00a0al (2023) Lecanemab in early Alzheimer\u2019s disease. N\u00a0Engl J Med 388(1):9\u201321","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"1463_CR17","doi-asserted-by":"crossref","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings\u00a0J, Lee\u00a0G, Nahed\u00a0P, Kambar\u00a0M, Zhong\u00a0K, Fonseca\u00a0J et\u00a0al (2022) Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 8(1):e12295","journal-title":"Alzheimers Dement (N Y)"},{"key":"1463_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, DuBois B, Fr\u00f6lich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P (2016) Drug development in Alzheimer\u02bcs disease: the path to 2025. Alzheimers Res Ther 8:39","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"1463_CR19","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel\u00a0H, Mesulam\u00a0MM, Cuello\u00a0AC, Farlow\u00a0MR, Giacobini\u00a0E, Grossberg\u00a0GT et\u00a0al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141(7):1917\u20131933","journal-title":"Brain"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01463-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01463-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01463-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T20:23:31Z","timestamp":1701721411000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01463-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1463"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01463-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"assertion":[{"value":"20 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Dodel gibt an, dass kein Interessenkonflikt bez\u00fcglich der Inhalte dieses Artikels besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}